Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting

Glucotrack, Inc.

Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.
Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.
Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.
Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.